AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023 | Evolving Opportunities with AstraZeneca and Boehringer Ingelheim | Technavio

January 6, 2020 GMT
Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023 | Evolving Opportunities with AstraZeneca and Boehringer Ingelheim | Technavio
Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023 | Evolving Opportunities with AstraZeneca and Boehringer Ingelheim | Technavio

LONDON--(BUSINESS WIRE)--Jan 6, 2020--

Technavio has been monitoring the global chronic obstructive pulmonary disease (COPD) drugs market since 2014 and the market is poised to grow by USD 3.52 billion during 2019-2023, progressing at a CAGR of almost 4% during the forecast period. Request a free sample report

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200106005627/en/

Technavio announced its latest market research report titled global chronic obstructive pulmonary disease (COPD) drugs market 2019-2023 (Graphic: Business Wire)

Read the 124-report with TOC on “Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Analysis Report by Product (Combination therapy and Monotherapy), Type (Chronic bronchitis and Emphysema), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2019-2023”.

https://www.technavio.com/report/global-chronic-obstructive-pulmonary-disease-copd-drugs-market-industry-analysis

The market is driven by a strong pipeline and new drug approvals. In addition, expanding research in curative approaches is anticipated to boost the growth of the chronic obstructive pulmonary disease (COPD) drugs market.

Vendors in the market are introducing combination drugs that provide a wide range of therapeutic benefits. Clinical studies on such drugs have demonstrated their advantages over other drugs currently available in the market. For instance, aclidinium bromide/formoterol is a twice-a-day drug combination, which has shown positive results in Phase III results. The drug significantly improved the functioning of lungs in patients with moderate to very severe, stable COPD. Hence, many drug manufacturers are adopting this approach and are making significant investments to develop once-a-day combinations. Many drug combinations are currently in the late stages of development and are expected to receive marketing approval during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for   free.

View market snapshot before purchasing

Major Five Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Companies:

AstraZeneca

AstraZeneca operates the business in the Biopharmaceuticals segment. The company offers a wide range of COPD drugs. SYMBICORT, DALIRESP, TUDORZA PRESSAIR, and BEVESPI AEROSPHERE are some of its key offerings.

Boehringer Ingelheim

Boehringer Ingelheim operates the business across segments such as Human Pharmaceuticals, Animal Health, and Biopharmaceuticals. The company offers a wide range of COPD drugs. SPIRIVA RESPIMAT/SPIRIVA HANDIHALER, SPIOLTO RESPIMAT, Striverdi Respimat, ATROVENT, and Berodual.

GlaxoSmithKline

GlaxoSmithKline operates the business across segments such as Pharmaceuticals, Vaccines, and Consumer Healthcare. Some of the key products offered by the company include TRELEGY ELLIPTA, INCRUSE ELLIPTA, BREO ELLIPTA, SEREVENT DISKUS, and VENTOLIN HFA.

Novartis

Novartis operates its business across segments such as Innovative medicine, Sandoz, and Alcon. UTIBRON NEOHALER, SEEBRI NEOHALER, and ONBREZ BREEZHALER are some of the key offerings of the company.

Teva Pharmaceutical

Teva Pharmaceutical operates the business across segments such as Generic Medicines and Specialty Medicines. DuoResp Spiromax and BRALTUS are the key offerings of the company. Both drugs are indicated for the treatment of adults with asthma and COPD.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Technavio has segmented the Chronic Obstructive Pulmonary Disease (COPD) Drugs market based on the product, type, and region.

Chronic Obstructive Pulmonary Disease (COPD) Drugs Product Outlook (Revenue, USD Billion, 2019 - 2023)

Chronic Obstructive Pulmonary Disease (COPD) Drugs Type Outlook (Revenue, USD Billion, 2019 - 2023)

Chronic Obstructive Pulmonary Disease (COPD) Drugs Regional Outlook (Revenue, USD Billion, 2019 - 2023)

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports onHealthcareare:

Global Therapeutic Vaccines Market – Global therapeutic vaccines market by type (cancer vaccines, infectious diseases vaccines, neurological diseases vaccines, autoimmune diseases vaccines, and other diseases vaccines) and geography (Asia, Europe, North America, and ROW).

Global Homecare Ventilator Market – Global homecare ventilator market by type (pneumatic ventilators, electronic ventilators, and electro-pneumatic ventilators) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at  media@technavio.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20200106005627/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

Follow Us: LinkedIn | Twitter

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Technavio Research

Copyright Business Wire 2020.

PUB: 01/06/2020 04:30 PM/DISC: 01/06/2020 04:30 PM

http://www.businesswire.com/news/home/20200106005627/en